Oura reaches $11 billion valuation with new $900 million fundraise

Oura reaches  billion valuation with new 0 million fundraise


The Oura Ring 4

Courtesy: Oura

Oura said Tuesday that it raised over $900 million in a new Series E funding round, bringing the company’s valuation to $11 billion.

The fundraise, led by Fidelity Management & Research Company, also includes new investor ICONIQ and contributions from Whale Rock and Atreides.

“With this investment, we will accelerate innovation, expand our global reach, and set a new standard for what wearables can achieve in advancing preventive health,” said CEO Tom Hale in a statement.

The Finnish company, which ranked No. 23 on CNBC’S 2025 Disruptor 50 List, has raised approximately $1.5 billion, according to a release.

Known for its Oura Rings, the company competes with other smart ring makers like Samsung and RingConn, as well as fitness-focused devices from Whoop and Garmin.

Oura announced in September that it has sold over 5.5 million Oura Rings since the product’s launch in 2015, a significant jump from 2.5 million rings announced in June 2024. The company reported revenue of over $500 million in 2024, more than double from the year prior, and expects to reach $1 billion in sales this year.

Looking to broaden further in the wearable category, Oura has also been expanding its features to compete with more general wearable devices like Apple or Samsung watches.

Along with its new Oura Ring 4 Ceramic, the company recently unveiled Health Panels, a blood testing feature that allows users to schedule and view their lab results directly in the Oura App.

Users can keep track of up to 50 biomarkers and can receive their health data summary as well as diet or activity suggestions from Oura’s AI-powered Advisor.

The ring maker also partnered with Dexcom, a leader in glucose monitoring technology, late last year to integrate Dexcom glucose data with biometrics collected by Oura so users can monitor their glucose levels.

“We’re proud to be building not just a product, but a global movement toward proactive health—helping people understand their bodies, make better lifestyle decisions, and connect more effectively with their healthcare providers,” Hale said.



Source

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to  billion
Health

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to $12 billion

A startup widely known as “ChatGPT for doctors” raised a new funding round that values the company at $12 billion. OpenEvidence, based in Miami, Florida, closed a $250 million financing, led by Thrive Capital and DST, the company told CNBC. The startup first raised outside capital in February, when it reeled in $75 million from […]

Read More
Another alliance of health care and AI signals why pharma stocks should be back in favor
Health

Another alliance of health care and AI signals why pharma stocks should be back in favor

Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the latest way health care and artificial intelligence are rapidly intersecting. Bristol Myers said on Tuesday it will work with Microsoft’s AI-powered radiology platform to develop and launch imaging algorithms. These new tools, which can be used to […]

Read More
Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
Health

Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry

US President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers […]

Read More